Biocon stock in green after Q3 profit jumps 5-fold to ₹144 CrBiocon stock in green after Q3 profit jumps 5-fold to ₹144 Cr

Introduction

Leading biopharmaceutical company reported Q3FY26 net profit of Rs 144 crore, up 475% YoY, with revenue at Rs 4,173 crore and EBITDA at Rs 951 crore.

Also Read: Ceigall Infra lands massive ₹2,160 Cr highway contract

Share price movement of Biocon

On February 13, 2026, Biocon Ltd opened at ₹372.20, down 0.81% from its previous close of ₹375.25. The stock reached a high of ₹381.10 (1.56%) and a low of ₹369.50. By 11:22 AM, it traded at ₹373.80, down 0.39%, with a market cap of ₹60,589.53 crore.

Biocon Q3 Profit Jumps

Biocon Limited reported a consolidated net profit of Rs 144 crore in Q3FY26, up 475% year on year from Rs 25 crore in Q3FY25, based on reported figures.

Revenue from operations rose 9% year on year to Rs 4,173 crore in Q3FY26, compared to Rs 3,821 crore in Q3FY25, reflecting steady business performance.

Total revenue increased 11% year on year to Rs 4,290 crore from Rs 3,856 crore. EBITDA rose 21% year on year to Rs 951 crore in Q3FY26.

Stock performance of Biocon for period of 1 week, 6 months, and 1 year

Biocon Ltd gained 2.64% over the past week and rose 4.40% in the past six months. The stock advanced 4.38% over the past one year.

Also Read: Radiant Cash Services receives LOI from IDBI Bank; check details

Shareholding pattern of Biocon

Particulars	Jan 2026	Dec 2025	Sep 2025
Promoter	44.90%	54.50%	54.50%
FII	7.10%	7.40%	6.60%
DII	24.20%	21.70%	22.10%
Public	23.70%	16.30%	16.70%

About Biocon

Biocon Ltd (NSE: BIOCON) is a biotechnology company engaged in manufacture of biotechnology products and provision of research and development services globally.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs